CpG-depleted adeno-associated virus vectors evade immune detection

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2994-3001

  Faust, Susan M ^a   Bell, Peter ^a   Cutler, Benjamin J ^a,c   Ashley, Scott N ^a   Zhu, Yanqing ^a   Rabinowitz, Joseph E ^b   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BETA GALACTOSIDASE; GAMMA INTERFERON; PARVOVIRUS VECTOR; TOLL LIKE RECEPTOR 9;

ADENO ASSOCIATED VIRUS; ARTICLE; CD8+ T LYMPHOCYTE; CPG ISLAND; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VIVO STUDY; MYOPATHY; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADAPTIVE IMMUNITY; ANIMALS; CAPSID; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CPG ISLANDS; DEPENDOVIRUS; DNA, VIRAL; GENETIC THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNE EVASION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; TOLL-LIKE RECEPTOR 9; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84879683527     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68205     Document Type: Article

References (27)

1. Brantly ML, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1- AAT gene therapy. Proc Natl Acad Sci U S A. 2009;106(38):16363-16368.
2. Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet. 2011;20(R1):R87-R92.
3. Flotte TR, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther. 2011;22(10):1239-1247.
4. Mendell JR, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010;68(5):629-638.
5. Mendell JR, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol. 2009;66(3):290-297.
6. Mendell JR, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010;363(15):1429-1437.
7. Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol. 2011;2:201.
8. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816-825.
9. Pahl JH, et al. Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling. Mol Immunol. 2012;51(1):91-100.
10. Rathinam VA, Fitzgerald KA. Innate immune sensing of DNA viruses. Virology. 2011;411(2):153-162.
11. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801. (Pubitemid 43261452)
12. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-745. (Pubitemid 32015992)
13. Stan AC, Casares S, Brumeanu TD, Klinman DM, Bona CA. CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. Eur J Immunol. 2001;31(1):301-310.
14. Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol. 1998;161(11):5943-5951. (Pubitemid 28535962)
15. Martino AT, et al. The genome of self- complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011;117(24):6459-6468.
16. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009;119(8):2388-2398.
17. Wu T, et al. Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther. 2012;20(3):572-579.
18. + T cell response to vector encoded proteins. J Immunol. 2009;182(10):6051-6060.
19. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76(9):4580-4590. (Pubitemid 34309593)
20. Zhao H, Hemmi H, Akira S, Cheng SH, Scheule RK, Yew NS. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther. 2004;9(2):241-248. (Pubitemid 38256550)
21. Ulmer JB, Otten GR. Priming of CTL responses by DNA vaccines: direct transfection of antigen presenting cells versus cross-priming. Dev Biol (Basel). 2000;104:9-14.
22. Fu TM, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997;3(6):362-371.
23. Bell P, et al. Evaluation of adeno- associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther. 2011;22(8):985-997.
24. Gao G, et al. Adeno-associated virus- mediated gene transfer to nonhuman primate liver can elicit destructive transgene- specific T cell responses. Hum Gene Ther. 2009;20(9):930-942.
25. Wang L, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther. 2010;18(1):126-134.
26. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A. 1999;96(7):3906-3910. (Pubitemid 29169009)
27. Lock M, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther. 2010;21(10):1259-1271.